Efavirenz + Emtricitabine + Tdf 600/200/300 mg Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 600/200/300 mg
Reference Brands: Atripla(US/EU)
Category: Anti Viral
Atripla Tablets (Efavirenz 600 mg, Emtricitabine 200 mg, Tenofovir 300 mg) offer a once-daily, fixed-dose HIV treatment. Available via PharmaB2B platforms from WHO-GMP and USFDA-approved suppliers, Atripla is ideal for bulk procurement, tenders, and HIV programs. Ensure reliable supply from trusted global manufacturers.
Product Description:
Atripla Tablets combine Efavirenz (600 mg), Emtricitabine (200 mg), and Tenofovir Disoproxil Fumarate (300 mg) in a once-daily, fixed-dose antiretroviral therapy for HIV-1 infection. Widely recommended in global HIV treatment guidelines, Atripla simplifies adherence and improves patient outcomes. On PharmaB2B platforms, global pharmaceutical buyers, NGOs, and procurement agencies can source WHO-GMP and USFDA-approved Atripla formulations from trusted manufacturers. Ideal for tender supply, HIV programs, and institutional purchases, Atripla is available for bulk export at competitive prices. Partner with verified suppliers on PharmaB2B to ensure timely, compliant delivery of high-quality antiretrovirals essential for public health programs.
Efavirenz + Emtricitabine + Tdf — third party manufacturing & bulk supply
Efavirenz + Emtricitabine + Tdf 600/200/300 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Efavirenz + Emtricitabine + Tdf listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Efavirenz + Emtricitabine + Tdf →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Efavirenz, emtricitabine, and tenofovir disoproxil fumarate (TDF) are used together as a single-tablet regimen to treat HIV-1 infection. This combination helps lower viral load, improve immune function, and prevent HIV progression when taken regularly.
It is made from three antiretroviral agents: efavirenz (a non-nucleoside reverse transcriptase inhibitor), emtricitabine (an NRTI), and tenofovir disoproxil fumarate (an NRTI). Together they block HIV replication at multiple stages.
The common trade name is Atripla.
Atripla is co-developed by Gilead Sciences and Bristol-Myers Squibb, with several generic manufacturers producing it globally.
The generic name is efavirenz, emtricitabine, and tenofovir disoproxil fumarate.
The primary brand name is Atripla.
It is manufactured in approved facilities in the USA, Europe, and India, depending on whether it is the innovator or a generic version.
Related Products
Brincidofovir
Strength:
100 mg, 10 mg/ml
Form: Tablets / Oral suspension
Reference Brands: Tembexa (USA/EU)
View Details
Lenacapavir
Strength:
300 mg, 463.5 mg/1.5 mL
Form: Tablet / Injection
Reference Brands: Yeztugo (USA), Sunlenca (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
